Skip to main content
Signal8

Next-Generation DNA Repair Inhibitors Could Capture Billions in Emerging Market

$GILDPress releaseJun 24, 2026, 8:30 AM ETRead the release

Gilead Sciences announced that the primary efficacy endpoint at Week 48 was met in both the phase 3 ISLEND-1 and ISLEND-2 trials for its investigational oral once-weekly single-tablet regimen of islatravir and lenacapavir. The trials evaluated the regimen in virologically suppressed patients switching from BIKTARVY or standard of care, with the safety profile generally comparable to comparators and no new safety concerns identified.

Key figures

Drug Name
islatravir/lenacapavir
Phase Of Trial
phase 3
Dosing
oral once-weekly single-tablet regimen of islatravir 2 mg/lenacapavir 300 mg

AI analysis

Red flags2 · Pro

The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.

AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.

    GILD: Next-Generation DNA Repair Inhibitors Could Capture Billions in Emerging Market — AI Analysis | Signal8